Olema Pharmaceuticals

OLMAPhase 3

Olema Pharmaceuticals is pioneering the development of next-generation endocrine therapies for hormone-driven cancers, particularly breast cancer. The company's lead program, palazestrant, is a novel oral CERAN/SERD designed to overcome limitations of current endocrine therapies, including resistance mechanisms. Olema has advanced palazestrant into late-stage clinical development, with a Phase 3 trial (OPERA-01) underway in metastatic breast cancer, positioning the company as a key player in the evolving breast cancer treatment landscape.

Market Cap

$1.2B

Employees

50-100

Focus

Biotech

OLMA · Stock Price

USD 14.08+9.61 (+214.99%)

Historical price data

AI Company Overview

Technology Platform

Platform focused on complete estrogen receptor antagonists (CERANs) and selective estrogen receptor degraders (SERDs) for hormone-driven cancers, with expertise in nuclear hormone receptor biology and drug optimization.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Palazestrant + Fulvestrant + Anastrozole + Letrozole + Exemestane	Breast Cancer	Phase 3
OP-1250	Hormone Receptor Positive Breast Carcinoma	Phase 1/2
OP-3136 + Fulvestrant + Palazestrant	Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)	Phase 1

Funding History

Total raised: $264.8M

IPO$204.8MUndisclosedOct 15, 2020

Series B$60MBVF PartnersJan 15, 2020

Opportunities

Significant opportunity exists in the large HR+ breast cancer market, particularly with an oral CERAN/SERD that offers CNS penetration and activity against ESR1 mutations.

Expansion into earlier treatment lines and combination regimens with CDK4/6 inhibitors could substantially increase the addressable patient population.

The evolving treatment paradigm favoring more potent endocrine therapies earlier in the disease course creates multiple commercialization pathways.

Risk Factors

Primary risks include clinical failure in Phase 3 trials, intense competition from multiple late-stage oral SERD/CERAN candidates, regulatory hurdles for approval, and commercial challenges against established pharmaceutical companies with larger oncology sales forces.

Financial risks include potential need for additional capital if trials are delayed or expanded.

Competitive Landscape

Olema faces competition from established endocrine therapies and emerging oral SERD/CERAN candidates from companies like Radius/Menarini (elacestrant - approved), Roche (giredestrant - Phase 3), and AstraZeneca (camizestrant - Phase 3). Differentiation centers on palazestrant's complete antagonist profile, CNS penetration potential, and favorable pharmacokinetics, but commercial success will require clear demonstration of superior efficacy or safety in late-stage trials.

Publications

Patents

Pipeline